FDA
approval
· 2022-12-19
FDA Approved: MICARDIS HCT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
Summary
The FDA approved a supplemental application for MICARDIS HCT (telmisartan and hydrochlorothiazide) from Boehringer Ingelheim Pharmaceuticals, Inc.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for MICARDIS HCT (TELMISARTAN AND HYDROCHLOROTHIAZIDE)